Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml
Synlett 2017; 28(14): 1801-1806
DOI: 10.1055/s-0036-1589033
DOI: 10.1055/s-0036-1589033
letter
Thieme Chemistry Journals Awardees – Where Are They Now?
Chiral Sulfinamide Ligands and Pd-Catalyzed Asymmetric Allylic Alkylations of Ethyl 2-Fluoroacetoacetate
Supported by:
National Science Foundation of China
21272175
Supported by: Shanghai Science and Technology Commission 14DZ2261100
Further Information
Publication History
Received: 16 March 2017
Accepted after revision: 18 April 2017
Publication Date:
08 May 2017 (online)
![](https://www.thieme-connect.de/media/synlett/201714/lookinside/thumbnails/st-2017-w0191-l_10-1055_s-0036-1589033-1.jpg)
Abstract
New chiral sulfinamide ligands made from salicylic acids and chiral tert-butanesulfinamide was utilized in Pd-catalyzed asymmetric allylic substitutions of ethyl 2-fluoroacetoacetate, which afforded the fluorinated allyl products with up to 98% yield, 94% ee, and 2.2:1 dr. Both sulfoxide and hydroxyl group on the sulfanilamide ligands are crucial for enantiocontrol in the Pd-catalyzed allylic alkylations of ethyl 2-fluoroacetoacetate.
Key words
sulfinamide ligand - allylation - palladium - enantioselectivity - fluorinated allylproductSupporting Information
- Supporting information for this article is available online at https://doi.org /10.1055/s-0036-1589033.
- Supporting Information
-
References and Notes
- 1a Bégué JP. Bonnet-Delpon D. Bioorganic and Medicinal Chemistry of Fluorine . Wiley; New Jersey: 2008
- 1b Kirsch P. Modern Fluoroorganic Chemistry: Synthesis, Reactivity, Applications. 2nd ed. Wiley-VCH; Weinheim: 2013
- 1c Hagmann WK. J. Med. Chem. 2008; 51: 4359
- 1d Furuya T. Kamlet AS. Ritter T. Nature 2011; 473: 470
- 1e Liang T. Neumann CN. Ritter T. Angew. Chem. Int. Ed. 2013; 52: 8214
- 1f Lectard S. Hamashima Y. Sodeoka M. Adv. Synth. Catal. 2010; 352: 2708
- 2a Chu CK. Cheng YC. Pai BS. Yao GQ. US Patent 5587362, 1996
- 2b Marcellin P. Mommeja-Marin H. Sacks SL. Lau GK. Sereni D. Bronowicki JP. Mondou E. Hepatology 2004; 40: 140
- 3 Montgomery JA. Shortnacy-Fowler AT. Clayton SD. Riordan JM. Secrist III JA. J. Med. Chem. 1992; 35: 397
- 4 Sorbera LA. Serradell N. Bolos J. Drugs Fut. 2007; 32: 12
- 5 Yamaguchi M. Yasueda SI. Isowaki A. Yamamoto M. Kimura M. Inada K. Ohtori A. Int. J. Pharm. 2005; 301: 121
- 6a Fukuzumi T. Shibata N. Sugiura M. Yasui H. Nakamura S. Toru T. Angew. Chem. Int. Ed. 2006; 118: 5095
- 6b Bélanger É. Cantin K. Messe O. Tremblay M. Paquin JF. J. Am. Chem. Soc. 2007; 129: 1034
- 7 FBSM was reported by Shibata and Hu, respectively, in 2006, see ref. 6a and: Ni C. Li Y. Hu J. J. Org. Chem. 2006; 71: 6829
- 8a Buchannan RL. Pattison FL. M. Can. J. Chem. 1965; 43: 3466
- 8b Harsanyi A. Sandford G. Org. Process Res. Dev. 2014; 18: 981
- 9a Kawasaki T. Kitazume T. Isr. J. Chem. 1999; 39: 129
- 9b Jiang B. Huang ZG. Cheng KJ. Tetrahedron: Asymmetry 2006; 17: 942
- 9c Shibatomi K. Muto T. Sumilkawa Y. Narayama A. Iwasa S. Synlett 2009; 241
- 9d For the use of FBSM in Pd-catalyzed asymmetrical allylations of symmetric di-substituted allylic substrates, see: Zhao X. Liu D. Zheng S. Gao N. Tetrahedron Lett. 2011; 52: 665
- 10a Liu WB. Zheng SC. He H. Zhao XM. Dai LX. You SL. Chem. Commun. 2009; 6604
- 10b Zhang H. Chen J. Zhao XM. Org. Biomol. Chem. 2016; 14: 7183
- 11 Zhu F. Xu PW. Zhou F. Wang CH. Zhou J. Org. Lett. 2015; 17: 972
- 12a Han X. Kwiatkowski J. Xue F. Huang KW. Lu Y. Angew. Chem. Int. Ed. 2009; 121: 7740
- 12b Li H. Zu L. Xie H. Wang W. Synthesis 2009; 1525
- 12c Yang W. Wei X. Pan Y. Lee R. Zhu B. Liu H. Yan L. Huang KW. Jiang Z. Tan CH. Chem. Eur. J. 2011; 17: 8066
- 12d Furukawa T. Kawazoe J. Zhang W. Nishimine T. Tokunaga E. Matsumoto T. Shiro M. Shibata N. Angew. Chem. Int. Ed. 2011; 50: 9684
- 12e Companyó X. Valero G. Ceban V. Calvet T. Font-Bardia M. Moyano A. Rios R. Org. Biomol. Chem. 2011; 9: 7986
- 12f Wang B. Companyó X. Li J. Moyano A. Rios R. Tetrahedron Lett. 2012; 53: 4124
- 12g Cosimi E. Engl OD. Saadi J. Ebert MO. Wennemers H. Angew. Chem. Int. Ed. 2016; 55: 13127
- 13a Trost BM. Van Vranken DL. Chem. Rev. 1996; 96, 395
- 13b Johannsen M. Jørgensen KA. Chem. Rev. 1998; 98: 1689
- 13c Hayashi T. J. Organomet. Chem. 1999; 576: 195
- 13d Helmchen G. Pfaltz A. Acc. Chem. Res. 2000; 33: 336
- 13e Dai L.-X. Tu T. You S.-L. Deng W.-P. Hou X.-L. Acc. Chem. Res. 2003; 36: 659
- 13f Trost BM. Crawley ML. Chem. Rev. 2003; 103: 2921
- 13g Trost BM. J. Org. Chem. 2004; 69: 5813
- 13h Trost BM. Machacek MR. Aponick A. Acc. Chem. Res. 2006; 39: 747
- 13i Lu Z. Ma S. Angew. Chem. Int. Ed. 2008; 47: 258
- 13j Dieguez M. Pamies O. Acc. Chem. Res. 2010; 43: 312
- 13k He H. Ye KY. Wu QF. Dai LX. You SL. Adv. Synth. Catal. 2012; 354: 1084
- 13l Liu WB. Xia JB. You SL. Top. Organomet. Chem. 2012; 38: 155
- 14a Glorius F. Angew. Chem. Int. Ed. 2004; 43: 3364
- 14b Defieber C. Grützmacher H. Carreira EM. Angew. Chem. Int. Ed. 2008; 47: 4482
- 14c Hayashi T. Aldrichimica Acta 2009; 42: 31
- 14d Feng CG. Xu MH. Lin GQ. Synlett 2011; 1345
- 15a Carreño MC. Chem. Rev. 1995; 95: 1717
- 15b Fernández I. Khiar N. Chem. Rev. 2003; 103: 3651
- 15c Robak MT. Herbage MA. Ellman JA. Chem. Rev. 2010; 110: 3600
- 15d Sipos G. Drinkel EE. Dorta R. Chem. Soc. Rev. 2015; 44: 3834
- 15e Trost BM. Rao M. Angew. Chem. Int. Ed. 2015; 54: 5026
- 16a Mariz R. Luan X. Gatti M. Linden A. Dorta R. J. Am. Chem. Soc. 2008; 130: 2172
- 16b Bürgi JJ. Mariz R. Gatti M. Drinkel E. Luan X. Blumentritt S. Linden A. Dorta R. Angew. Chem. Int. Ed. 2009; 48: 2768
- 17a Chen J. Lang F. Li D. Cun L. Zhu L. Deng J. Liao J. Tetrahedron: Asymmetry 2009; 20: 1953
- 17b Liu J. Chen G. Jing X. Liao J. Tetrahedron: Asymmetry 2011; 22: 575
- 17c Du L. Cao P. Xing J. Lou Y. Jiang L. Li L. Liao J. Angew. Chem. Int. Ed. 2013; 52: 4207
- 18a Jin SS. Wang H. Xu MH. Chem. Commun. 2011; 7230
- 18b Jin SS. Wang H. Zhu TS. Xu MH. Org. Biomol. Chem. 2012; 10: 1764
- 19 Feng X. Wang Y. Wei B. Yang J. Du H. Org. Lett. 2011; 13: 3300
- 20 Chen Q. Chen C. Guo F. Xia W. Chem. Commun. 2013; 6433
- 21a Gao N. Zhao XM. Cai CS. Cai JW. Org. Biomol. Chem. 2015; 13: 9551
- 21b Zhang M. Zhao MZ. Zheng PR. Zhang HB. Zhao XM. J. Fluorine Chem. 2016; 189: 13
- 22 Typical Procedure for the Synthesis of (R)-L1 To a solution of salicylic acid (1.0 mmol) in THF (2.0 mL) was added 1,1′-carbonyldiimidazole (CDI; 1.0 mmol, 1.0 equiv) slowly at room temperature, then the reaction mixture was heated to 50 °C for 1.0 h. The solution was cooled to room temperature and concentrated to give the active amide. To a suspension of KH (30% in oil, 2.0 mmol, 2.0 equiv) in THF (5.0 mL) was added (R)-tert-butanesulfinamide (1.0 mmol) under argon at room temperature and the mixture was stirred for 0.5 h. The active amide was added and the mixture was stirred at 50 °C for 1.0 h. The reaction mixture was cooled to room temperature and acidified with aqueous HCl to pH >7, then the mixture was diluted with EtOAc (10 mL), washed with H2O (3 × 10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by column chromatography on silica gel (EtOAc) to give the desired product (R)-L1 (149.4 mg, 62% yield) as a white solid; mp 144.6–145.9 °C; [α] d 25 –73.8 (c = 1.0, MeOH). 1H NMR (400 MHz, CDCl3): δ = 7.78 (d, J = 7.8 Hz, 1 H), 7.39 (t, J = 7.4 Hz, 1 H), 7.01 (d, J = 8.1 Hz, 1 H), 6.88 (t, J = 7.5 Hz, 1 H), 1.36 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ = 168.94, 159.16, 135.22, 129.55, 119.79, 118.01, 115.40, 57.05, 22.26. IR (KBr): 3259, 2963, 2930, 2854, 1677, 1605, 1464, 1408, 1393, 1304, 1232, 1107, 1032 cm–1. HRMS (ESI-TOF): m/z [M + H]+ calcd for C11H16NO3S: 242.0845; found: 242.0841
- 23 CCDC-1499293, (R)-L1, contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures
- 24 Takaya H. Mashima K. Koyano K. Yagi M. Kumobayashi H. Taketomi T. Noyori R. J. Org. Chem. 1986; 51: 629
- 25 Abbenhius HC. L. Burckhardt U. Gramlich V. Kollner C. Pregosin PS. Salzman R. Togni A. Organometallics 1995; 14: 759
- 26 Trost BM. Van Vranken DL. Bingel C. J. Am. Chem. Soc. 1992; 114: 9327
- 27 Typical Procedure for Pd-Catalyzed Allylic Alkylation Reaction [Pd(C3H5)Cl]2 (0.004 mmol, 4 mol%), (R)-L1 (0.008 mmol, 8 mol%), and (E)-1,3-disubstituted allyl acetate 1 (0.1 mmol) were dissolved in THF/dioxane (2.0 mL, 1:1) in a dry Schlenk tube filled with argon. The reaction mixture was stirred for 30 min at room temperature, then ethyl 2-fluoroacetoacetate (2a; 0.3 mmol, 3.0 equiv) and K3PO4 (0.3 mmol, 3.0 equiv) were added. The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC. Upon completion, the mixture was filtered through Celite and the solvent was evaporated under vacuum. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate) to give the desired products 3a–i. (E)-Ethyl 2-Acetyl-3,5-bis(3-chlorophenyl)-2-fluoropent-4-enoate (3a): Colorless oil (39.8 mg, 98% yield). The diastereomeric ratio was 1.6:1 determined by 1H NMR spectroscopic analysis. The ee value of the major diastereomer was 80%, the minor diastereomer was 78%, determined by chiral HPLC [Daicel CHIRALCEL OJ-H (0.46 cm × 25 cm); hexane/i-PrOH = 98:2; flow rate = 1.0 mL/min; detection wavelength = 254 nm; tR (major) = 16.984, 19.423 min; tR (minor) = 21.968, 25.166 min]. 1H NMR (400 MHz, CDCl3, stereoisomeric mixture): δ = 7.42–7.17 (m, 13 H), 6.61–6.21 (m, 3.3 H), 4.52 (dd, J = 32.6, 8.8 Hz, 1.6 H), 4.37–4.16 (m, 2 H), 4.06 (m, 1.3 H), 2.32 (d, J = 5.7 Hz, 1.9 H), 2.01 (d, J = 5.6 Hz, 3 H), 1.27 (t, J = 7.1 Hz, 3 H), 1.06 (t, J = 7.1 Hz, 1.9 H). 13C NMR (100 MHz, CDCl3, stereoisomeric mixture): δ = 201.32 (d, J = 29.8 Hz), 201.14 (d, J = 29.9 Hz), 164.66 (d, J = 25.7 Hz), 164.26 (d, J = 25.9 Hz), 139.01, 138.42, 138.10, 138.03, 134.60, 134.46, 133.61, 133.30, 130.04, 130.02, 129.85, 129.52 (d, J = 2.5 Hz), 129.19 (d, J = 2.6 Hz), 128.11, 128.06, 128.05, 128.00, 127.70 (d, J = 2.2 Hz), 127.12 (d, J = 2.6 Hz), 126.38, 126.33, 125.79, 125.75, 125.60, 125.55, 124.89, 124.80, 102.68 (d, J = 206.1 Hz), 102.52 (d, J = 207.9 Hz), 63.09, 62.84, 52.88 (d, J = 18.1 Hz), 52.82 (d, J = 18.2 Hz), 26.85, 26.84, 14.18, 13.77. 19F NMR (376 MHz, CDCl3, stereoisomeric mixture): δ = –174.49, –175.05. IR (KBr): 3064, 2982, 2932, 2854, 1754, 1734, 1594, 1570, 1476, 1431, 1356, 1246, 1205, 967, 913, 781, 742 cm–1. HRMS (ESI-TOF): m/z [M + Na]+ calcd. for C21H19Cl2FNaO3: 431.0587; found: 431.0592
For selected papers, reviews, and books, see:
For selected examples, see:
For the use of 2-fluoromalonate in Pd-catalyzed asymmetrical allylations, see:
For recent reviews, see:
For selected papers and reviews, see:
For selected reviews, see: